Pulitzer Prize nominated financial journalist reveals …
FDA’s Hidden Signal Greenlights Biotech Winners — 97% of the Time
The next signal is coming, perhaps as soon as 9:30 a.m. tomorrow.
Here’s how to spot it …
Dear Reader,
Hello, I’m Michael Robinson.
Don’t let the mainstream media fool you.
AI is not the only hot sector in the market.
Biotech is on fire as well.
In fact, the list of 2024’s best stocks is peppered with biotech names.
Like Arcutis Biotherapeutics, up 212% this year alone.
Or Janux Therapeutics, up 278% already in 2024.
Viking Therapeutics is up 210% so far this year.
There’s only one problem for investors.
Unless you have a PhD …
Or an inside source …
Good luck picking biotech winners ahead of time.
The FDA approval process is extremely difficult.
It can cost billions of dollars …
And can last for more than a decade.
Even then, after multiple phases of trials, a drug can still be rejected.
In fact, 9 in 10 drugs never get approval from the FDA.
They die on the vine.
And even for the ones who survive, it can be hard to get any information on the status of a drug …
Or how close it is to approval.
The FDA is notoriously opaque.
But for a special set of drug companies, all of that has changed.
The FDA has started to quietly send out a signal …
This signal means these specific companies will get an expedited route to approval …
And hands-on guidance from the FDA.
You could say these are some of the FDA’s favorite companies.
But from an investor standpoint, there’s something more important going on here …
Over 97% of the time the FDA sends out this signal – the company involved has seen its stock spike at some point in the following months.
Let me be clear.
There are a number of reasons why a stock may have gone up beyond just this signal.
And keep in mind, this signal is not approval.
This spike comes long before a final decision is made on the drug.
It hasn’t mattered if it gets approved or rejected.
Since this signal was created, investors who bought on the day the FDA announced it, they would’ve had a 97% chance of making money.
Take Adaptimmune Therapeutics, for example.
Shares were hovering around one dollar when the FDA sent out this quiet signal on Adaptimmune’s new tumor drug.
Within six months, shares shot up 845% …
It took almost four more years before the drug was approved.
Caladrius Biosciences’ stock was going nowhere, stuck around $4 …
Then it got this FDA signal.
And shares jumped 119% -- in two days.
The drug in question wasn’t approved for another five years …
Ocugen received an FDA signal in December 2023.
Its share price spiked 435% in just five months.
The drug has yet to be given final approval.
63 different publicly traded companies have received 76 of these signals between them in the last seven years.
We examined every single one.
Almost every one of them saw the stock price go up in the aftermath.
97%.
And whether the drug was eventually approved or not had no effect …
It’s a simple trade. The FDA sends out this signal.
And 97% of the time the company’s stock price goes up in the following months.
The average gain was 117% in eight months.
Now, I believe one drug company is on the verge of getting this FDA signal.
In fact, I think it could happen very soon …
But, even more exciting, I expect this company to get multiple signals in the coming months …
That means this isn’t just a short-term trade …
This is a long-term play.
This could be one of the world’s next biotech leaders.
It’s all thanks to a breakthrough technology that’s turning medicine on its head.
It has the potential to cure some of the deadliest diseases in the world.
Like diabetes …
Genetic cardiovascular disease …
Hepatitis B …
Sickle Cell …
And it could drastically reduce the death rate of brain cancer, melanoma, colorectal cancer, blood cancer …
Even non-Hodgkin’s Lymphoma.
Before he died, Stephen Hawking said of this tech:
“With (it), we will be able, …. to improve the human race.”
And Nvidia’s CEO, Jensen Huang, says he thinks this medical breakthrough will be “the next amazing revolution.”
In a moment, I’ll talk more about this groundbreaking biotech – and why it could spur dozens of stock market winners.
But first, let me introduce myself – and explain how I came to discover this FDA signal …
That tips investors off to promising biotech stocks – ahead of time.
I called Nvidia at 80 cents …
My name is Michael Robinson.
As an investigative financial journalist, I’ve spent years getting to the bottom of the biggest stories on the stock market.
To help investors understand what’s really going on …
And to help them spot promising stocks ahead of time.
For instance, here are a few of my biggest winners.
I recommended AI superstar Nvidia back in 2016 when the share price was a 80 cents, adjusted for stock splits.
And shares have been up 17,062% since I spotted them.
I met some of the first Bitcoin investors – including the famous Winklevoss twins – way back in 2013.
And I recommended the cryptocurrency when it was just $300.
It’s been up 21,932% since.
When the iPhone was taking off, I told Fox Business Apple’s shares would soon hit $1,000.
Two years later, adjusted for stock splits, Apple’s share price was $2,800.
My ability to stay ahead of the crowd has led to my work being featured in The New York Times.
I’ve appeared on CNBC and Fox Business.
I’ve even been nominated for a Pulitzer Prize.
But nothing compares to the massive breakthroughs happening in biotech right now.
And I’ve been at the forefront of this sector as well.
Here are some of my most successful calls …
I recommended biotech cloud pioneer Veeva Systems – leading to a 372% gain in a little over 3 years.
I picked Novavax for a 316% gain in 15 months.
And in June 2020, while Covid raged around us, I made 375% in just under two months on oral vaccine pioneer Vaxart.
But now, thanks to this quiet FDA signal …
Investors can spot potential biotech winners ahead of time.
At an astonishing rate.
142% in 5 Days? FDA signal linked to astonishing gains …
We dug into every time the FDA sent this signal …
And how it affected the price of the stock involved.
It turns out, of 63 publicly traded stocks that received 76 of these FDA signals …
The stock price went up in the aftermath – 97% of the time.
In some cases, the gains were rapid …
Like, Sangamo Therapeutics, up 142% in five days after getting the FDA’s signal.
UniQure saw its stock price double in just over a month after receiving the FDA signal.
Shares of Organogenesis jumped 201% less than four months after getting the FDA signal.
CARsgen Therapeutics’ stock skyrocketed 268% just six months after it got the signal.
And these aren’t just short-term trades …
Many of these stocks kept going up in the months and years after the FDA signal.
Vericel was still going up over four years later. The overall gain was 2,188%.
Rocket Pharmaceutical’s stock price climbed 308% in just over two years after they got the FDA signal.
Mesoblast saw a 251% gain in 30 months post-signal.
So, what’s going on here?
This FDA signal doesn’t get big headlines.
It’s barely publicized.
Yet it has led to stock market winners 97% of the time?
I’ve spent the last 30+ years as an investigative financial journalist …
Getting to the bottom of some of the biggest stories in the market.
I even wrote a critically acclaimed expose on the Savings and Loan Crisis, called Overdrawn.
My team and I spent the last couple months – and thousands of dollars – to get to the bottom of this FDA signal.
When I initially saw the results, I was stunned.
As a critical thinker, I assumed there was a mistake.
Nothing goes up 97% of the time, right?
So I ran through the whole thing a second time with my analysts, to double check.
This is what the data shows.
76 times a publicly traded company received this signal.
And 97% of the time the stock went up.
The truth is, this signal has been a tip-off.
Companies who receive it have a much better chance at drug approval.
In fact, typically only 9% of all drugs receive FDA approval.
That’s barely one out of ten.
But companies who receive the FDA signal?
They have been approved 74% of the time …
That means these drugs are nearly eight times more likely to get approved.
You can count the rejections on one hand.
So in my opinion, there’s no point in waiting for approval or rejection to invest.
If the company receives this FDA signal, then it’s got an outstanding chance at eventual approval.
The data is telling me that the signal is the time to invest.
That’s when the market seems to price in approval.
Like 633% in five years on Krystal Biotech.
And that stock was up 65% in the first month alone.
Humacyte returned 79% in the first month.
And Longeveron was up 53% in three days.
So what’s the story here?
Has the FDA gone soft?
The truth is, for most companies, it’s just as hard to get a drug approved as it always has been.
But for a select group of companies, the FDA has created a greased path.
What we are calling a “First-Class” designation.
FDA hands out “First-Class” benefits to select drug companies …
Ever stood in a long line at the airport and wondered why some people get to skip the wait?
You see those same people at the gate, boarding the plane before you.
These are typically the benefits of purchasing a “First-Class” ticket.
First-class passengers get treated differently than the rest of us.
And a similar thing is going on at the FDA.
In 2016, the federal government created a law that gives certain drug companies “First-Class” status with the FDA.
That means they get treated differently than other drug companies.
Often, it takes a decade, billions of dollars and a ton of research to reach Phase 3 FDA approval.
First-Class drugs get expedited approvals and priority reviews. They shoot to the front of the line.
And that’s not all …
The FDA holds their hand the whole way.
Companies with this special First-Class designation get more face time with the FDA.
The federal drug regulator even gives them advice on how to structure trials for the best chance at approval.
You can see how this First-Class designation would give some companies the inside track.
And that’s exactly what happens. The FDA hands out First-Class tickets early in the process.
And companies who receive this First-Class designation …
Have a 74% record of approvals.
That’s 8 times better than the average, non-First-Class drugs.
The FDA signal I was talking about earlier … is simply the moment when the drug receives First-Class status from the FDA.
It’s almost always announced by the company itself.
I dug deep into this story, researching every single First-Class designation given out since 2016.
Of the 63 publicly traded companies to receive this special status 76 times from the FDA …
The stock price went up after the announcement 97% of the time.
Almost every single one.
And the average gain was 117% in eight months.
So what’s going on here?
Are certain drug companies paying their way to approval?
Well, no, it’s actually much less sinister than that.
These drugs are gaining First-Class status because the government has deemed them necessary in treating serious diseases or life-threatening conditions.
But they all have something else in common …
A small handful of these First-Class drugs utilize a brand-new type of technology.
One that could take over the medical world.
The company I’m highlighting today uses this type of advanced medicine.
And I think it’s the next biotech stock to explode.
In fact, I could see them becoming the industry leader.
Even better, I believe they’re due to get an FDA signal any day now.
Nobody knows for sure, but the announcement could happen tomorrow morning at 9:30 a.m. Eastern time, when markets open.
But when and if it happens, tomorrow, next week or a month from now – it’s likely to have a positive impact on the stock …
Beyond that, this company could receive multiple signals this year.
The Next FDA signal could come any day …
This company got its first FDA signal back in 2020.
And at its peak it’s been up nearly 80% since then.
But that was just the first breakthrough in what could be a long line of successful drugs.
You see, most of the time, a drug company forms because of a discovery – a group of scientists in a lab created a drug that could cure a certain disease.
Then they meet with investors and start a company – solely focused on the one disease their discovery treats.
The company I’m most excited about in biotech does it the opposite way.
They specifically look to treat diseases that serve a large market and can turn a profit.
They aren’t tied to just one drug or disease.
And I believe that helps put them in the good graces of the FDA.
Ultimately, the government regulator’s job is to get safe, effective drugs on the market for people in need.
And certain diseases are considered a top priority …
Especially serious or life-threatening diseases with very few effective drugs on the market.
The FDA will prioritize drug companies who put these drugs in their pipeline, to fill the need.
So they do whatever they can to encourage production … like offering First-Class status to any drug that treats one of these diseases.
And this First-Class status includes expedited approval, priority review and hands-on guidance.
As it turns out, many of these high-priority diseases are also potential cash cows.
And the company we are talking about today is working hard to pick off these diseases one-by-one.
They’ve already received First-Class designation – and approval – for a groundbreaking new drug that treats a nasty disease that often affects the lungs.
This disease effects over 100,000 Americans a year.
It’s typically discovered when the person is a baby.
In the past, without effective treatment, most patients with this disease failed to live past elementary school.
Now, this company is going out of its way to treat the diseases on the FDA priority list – starting with this debilitating lung disease.
They have over 97 different drugs in the pipeline.
And we believe that many of them could get the FDA’s special designation.
That’s why I think it’s so important to get in before any potential signals.
Because when the FDA sends this signal, the stock has gone up 97% of the time.
With an average gain of 117% in the first eight months.
This company has a ton of potential, because of its incredibly diverse pipeline.
Fast Company called it one of the 50 most innovative companies of 2024.
Time Magazine named them in their 100 most influential companies of 2024 list.
And they may eventually get enough FDA signals that we lose track.
I believe their next drug to get First-Class status is right around the corner.
The company could announce it any day.
But I want to stress again …
I don’t see this as a short-term trade.
I think this is a biotech company to own for the foreseeable future.
But it’s not because of the diseases they treat.
It’s because of something else up their sleeve.
A unique technology that may be the most important breakthrough of the 21st century.
It’s the secret behind this company’s ability to develop drugs that may treat multiple diseases at the same time.
And it’s a type of medical technology the FDA is throwing its full weight behind.
Meaning it could get the “First-Class” treatment in the approval process.
Which could mean a quicker route to drug approval and growth for the company.
And it’s this technology I’m most excited to tell you about today.
Because I think in the next decade, it’s not only going to be the source of massive growth.
It may save millions of lives in the process.
Nobel Prize breakthrough turns medicine on its head …
It’s a Nobel Prize technique that is changing medicine as we know it.
It’s impact on the world could be even bigger than the polio vaccine …
The creation of antibiotics …
Or the invention of the X-ray.
With the diseases this technology has in its sights, over two million deaths could’ve been prevented in the last year alone.
I’m talking about diabetes …
Sickle cell disease …
Genetic cardiovascular disease …
And that’s not even counting the impact this breakthrough could have on cancer treatment.
From blood cancer to brain cancer, early signs are this new medical tech could increase the life expectancy of cancer patients.
That’s why Bill Gates – a longtime supporter of this technology and the company I’m recommending today – called it:
“One of the most powerful technologies of the 21st century.”
Before he passed away, scientist Stephen Hawking said, “With genetic engineering, we will be able to increase the complexity of our DNA and improve the human race.”
And the US government called the Human Genome Project, “The single most influential investment to have been made in modern science.”
But this isn’t a pill …
Or any drug in the traditional sense.
This is a whole new way of treating disease.
The End of Pills …
You see, most diseases are hereditary.
They are present in your genes, your DNA.
Scientists have now developed a way to potentially go in and fix your DNA, removing the disease altogether.
It’s just being perfected right now.
The company I’m talking about today is at the forefront of that revolution.
In fact, they got the first FDA First-Class designation given specifically for this tech.
So what is it?
How does it go in and change your DNA?
I won’t get too scientific on you, but over the last decade, we’ve been able to map 100% of human DNA.
We know which strands control which functions. And where errors in the DNA can cause disease.
This new technology can enter the body’s DNA and remove or change the error causing the underlying disease.
If that’s done, there is no more treatment necessary.
No more giant pill cases with multiple doses per day.
No more vaccines.
No more laborious chemotherapy treatments.
It goes in, cuts out the DNA and replaces it.
You can see why Elon Musk said that one of the things that will most affect humanity is ”…the ability to reprogram the genetic code, or genome.”
Craig Venter, director of the Human Genome Project, which helped map DNA, said:
“The prospects of eliminating disease and improving longevity are within our grasp.”
MIT called it “life changing.”
And Harvard Medical School says, “The world stands on the edge of an era.”
The great news for investors is … we’re at the very beginning of this revolution.
There are currently 84 trials under way, treating dozens of ailments.
All using this new biotech breakthrough.
It could possibly eliminate 9 out of the top 10 most deadly diseases in the world …
That’s a bigger impact than any other medical breakthrough in history.
But of those promising trials, 88% of them are in the early stages.
Which means now is the time to take action …
Before this technology potentially takes over the world.
The Next Trillion Dollar Company?
I’ve been embedded in the tech industry for decades.
And this is the most important technology I’ve seen.
I truly believe it’s going to create numerous stock market winners in the next few years.
And if investors know where to look, they could ride this wave too.
The company I’m most excited about already got approval for a First-Class drug using this technology.
But I believe that was just the start …
This company spent $100 million to acquire another treatment from a smaller company.
And they have multiple treatments for various diseases in the early stages of their pipeline.
In addition, I believe every single one of them is up for First-Class designation.
In fact, since the FDA signal was created in 2016, this company has grown five times bigger.
But I think its use of this medical breakthrough means it will be at the forefront of this revolution in the coming years.
In fact, I believe it’s not out of the question this company could become the next trillion-dollar company once drug revenues start rolling in.
Because on top of this technology and all of the drugs in their pipeline.
This drug company is also ahead of the game when it comes to artificial intelligence.
Not only does AI drive the research process, helping identify and map DNA strands much quicker …
But AI has drastically improved the delivery method.
Again, without getting too scientific for the layman …
This DNA editor enters the body through special molecules …
At first, companies utilizing it had to find these molecules in nature – out of gazillions of others.
AI is creating brand-new molecules on its own.
The time this saves and efficiency this creates in the process is almost immeasurable.
That’s why I think now is the right time for investors to take a hard look at these companies.
These advances are only going to come more rapidly.
And as they do – and as these drugs get out of the early stages and start bringing in revenue …
I believe the mainstream stock market is going to go crazy for these companies.
If you’re interested, I’d like to send you my full investigative report on the company I think is best positioned for these exciting times.
They have numerous treatments in their pipeline.
And they utilize AI in combination with this medical breakthrough.
Not only that, but I expect one of their drugs to receive First-Class designation in the near future.
As you know, that is the FDA’s signal … This drug has a much better chance of approval.
And 97% of the time the FDA sends this signal, the stock goes up.
I’ve put all of the information about this company’s drug pipeline, the diseases they’re treating …
And why I think they could be the world’s next trillion-dollar company …
In my special report, The Next FDA Signal: How to Profit Off First-Class Drugs.
You’ll get the same level of information in this report as I share in boardrooms with the companies I advise.
On top of giving you the full scoop on this exceptional biotech company, I’ll share the name of a second company in this report as well …
This company is more of a moonshot because at the time of recording, the stock trades for under $10.
But with the technology they’re using that could change going forward.
That’s because this company works with the same technology.
And it has a very good chance of getting First-Class status on multiple drugs.
But it’s flying under the radar because right now, very few people understand how it’s going to revolutionize medicine, potentially eliminate pills and even chemotherapy – and possibly increase human longevity.
With biotech as the hottest sector right now …
Combined with the excitement behind this breakthrough technology.
I believe it’s only a matter of time before the market figures it out.
My research is telling me there is a window of opportunity right now.
If you think about it, very few people knew what artificial intelligence was or what its impact would be three years ago.
But they sure know now.
And investors have obviously figured it out.
AI has drove the so-called Magnificent 7 – Nvidia, Apple, etc. – up 49% in the first half of 2024..
Three of the four most valuable companies in the world are tech and AI related.
So if the tech brings in revenue, you can bet the market will notice.
And the approval rate of this new technology is so high, I believe we are going to see a flood of new treatments.
Everything is telling me that now is the time to invest.
The Most Important Technology I’ve Ever Seen …
Incidentally, I recommended Nvidia eight years ago.
Way before the AI craze.
It was just $.80 split adjusted.
Now, it’s up 17,062%.
I’ve been in Silicon Valley for years – first working for The San Francisco Examiner.
And then as an investigative financial journalist.
The access I gained helped me discover dozens of profitable tech stocks.
I was actually in the room when the term “cloud computing” was created.
My book, Overdrawn, uncovered the Savings and Loan scandal.
And I was also nominated for a Pulitzer Prize.
But I’m more proud of the stock market winners I’ve recommended.
Like 171% on TechTarget.
179% on Natera.
181% on Enphase Energy.
Even 563% on Digital Turbine.
From 2011 to 2022, when sharing my stock market recommendations …
Every single trade I’ve given has gained 24% on average.
And that includes ALL my winners and losers.
But I can honestly say …
This combination of biotech and AI is potentially the most important technology I’ve ever seen.
In my opinion, its impact on humanity is incomparable to anything else in history.
I expect its impact on the stock market to be outsized as well.
And the two companies I’ve been talking about today are likely to benefit in the very near term.
In fact, I expect both to receive FDA signals in the coming weeks.
And every time that’s happened historically, the stock has gone up.
Beyond that, with their pipelines, I think they could dominate the space for years to come.
In a moment, I’ll give you a chance to claim a copy of my special report, The Next FDA Signal: How to Profit Off First-Class Drugs.
Inside, you’ll get the name of both stocks …
My price expectations …
And for the tech enthusiasts out there, I go deeper on this breakthrough medical technology and how it’s going to revolutionize medicine.
You can have all of this valuable information at your fingertips in just a few minutes.
But first, I want to explain something.
This isn’t the only way AI is impacting drug companies.
In fact, AI is being put to use in multiple ways.
And it’s upending how long and how expensive it can be to develop a drug …
AI is Medicine’s Best Friend …
Artificial intelligence is all the rage right now.
And rightfully so.
Stocks like Nvidia – which I picked way back in 2016 – are soaring.
The chip giant is up 112% this year alone.
And 17,026% since I picked it.
I scored 107% in two years on Microsoft right before it soared on AI.
156% in 21 months on Dexcom, a little-known company using artificial intelligence.
And it seems like just adding AI to a company’s name had a positive effect on the stock price.
Obviously, artificial intelligence is a gamechanger for technology.
It’s been promised for years.
And it’s finally making a tangible difference in our lives.
The speed at which AI can complete tasks is turning whole industries on their head.
But I believe AI’s biggest impact is in medicine.
In fact, AI applications could potentially create $350 billion a year in annual value for pharma companies by 2025.
Beyond what I told you earlier about how it creates new molecules for gene editing purposes …
AI is rapidly improving the drug discovery process in numerous ways …
Its ability to process large volumes of data is invaluable.
The AI can sift through years and volumes of lab experiments in a matter of days … and suggest the most optimal solution.
“Now you can do 10,000 experiments simultaneously, get the results, then use those to design the next 10,000 experiments,” one top doctor said.
It can test compounds and molecules in a fraction of time …
And it can drastically reduce the amount of patients needed for a trial.
Using AI reduces the time needed for drug trials by 80%.
And it cuts the cost of drug development by 70%.
What does all this mean?
I believe AI’s growing use in the drug industry is going to lead to more drugs getting approved …
In a lot less time.
The FDA is already seeing a rapid uptick in applications for drugs created or aided by AI and machine learning.
But I believe one company is ahead of all these others.
Microsoft’s Silent Pharma Partner
Besides the stocks I’ll tell you about in your special report, The Next FDA Signal …
There’s another biotech company I’m very excited about.
And it’s because of their potential to drastically reduce the time it takes to get a drug approved.
Like I mentioned, it takes years and millions of dollars to earn FDA approval.
But this company believes they can cut the testing time down to just a matter of days.
And they’ve partnered with AI leader Microsoft to do it.
This would radically change medicine as we know it.
And it could put this company in the driver’s seat.
Its drug development technology could dominate anyone out there.
But here’s the thing …
This company already has a handful of high-performing drugs on the market.
So it receives a steady stream of cash – nearly $5 billion in profit last year.
And they have a deep pipeline with multiple potential winners.
But I believe the market has them sized up all wrong.
Because the so-called experts have no idea how valuable this company’s AI business is.
In a few years, they could be the dominant player in AI and drugs.
If you’re interested in learning more about this company, I just put the finishing touches on a comprehensive special report.
It’s called, The Ultimate AI Drug Stock.
Inside, I’ll tell you more about the hidden AI gold mine inside this drug company.
And how it could take their annual revenues to a whole new level.
I’ll share my optimal buy price for the stock.
And what my long-term expectations are.
Now here’s the best part:
You can claim a copy of The Ultimate AI Drug Stock
AND
The Next FDA Signal
As a bonus.
Right now.
You’ll get my three most valuable biotech recommendations …
Rushed to your inbox immediately.
I only ask one favor.
Give my monthly newsletter, Disruptors & Dominators, a try.
Silicon Valley Visionary Shares His Latest Tech Picks …
I’ve been an advisor to 12 high-tech startups in Silicon Valley.
I’ve served on the advisory board of a deep-pocketed venture capital fund.
I’ve appeared on Fox Business and CNBC.
My investigative exposés have made it into the pages of The New York Times and The San Francisco Examiner.
And I’ll share my latest tech recommendations with you, in my monthly newsletter, Disruptors & Dominators.
As the name implies, this newsletter strives to show you both sides of the great technology innovations we see in the world today.
It covers new, rapidly emerging companies that disrupt the world for the better.
And, at the same time, it also covers the well-established companies that already lead their industry.
That’s what I consider the best of both worlds …
The opportunity for faster, often explosive growth …
Plus the chance for safer, longer-term, sustainable growth.
For my money, I want both.
And that’s what you’ll get when you become a member of Disruptors & Dominators.
I’ve been in Silicon Valley for decades now.
And my access as a journalist has tipped me off to some of the biggest breakthroughs in history …
Well ahead of the market.
I already told you about Nvidia …
I recommended it at $0.80 way back in 2016.
It’s up 17,026% since.
I was early on Bitcoin as well.
I recommended it in 2013.
It’s been up 21,932% since.
And digital payment company Square, has been up 702% since my recommendation in 2016.
Several years ago I appeared on Fox Business and predicted, a bold call at the time, that Apple would soon be a $1,000 company.
I thought the host Stuart Varney was going to fall out of his seat.
Today, adjusted for stock splits, Apple was well over $2,800.
From 2011 to 2022, when sharing my stock market recommendations …
Every single trade I’ve given has gained 24% on average.
And that includes ALL my winners and losers.
But in Disruptors & Dominators, you get something even more special.
I’m combining my stock expertise with the 53-year track record of Weiss Ratings.
Weiss Ratings “Buy”-rated tech stocks average 279% gains – including the losers …
Weiss Ratings was founded by Martin Weiss with one express purpose:
To give regular Americans the tools they need to beat Wall Street.
And we’re proud to say we’ve achieved that goal and then some.
Weiss gives “Buy”, “Sell” and “Hold” ratings to nearly 12,500 stocks.
And in the last 20 years, the average gain for every “Buy” rated tech stock is 279%.
That includes the losers …
Winners like 39,864% on Apple …
27,893% on Nvidia when we recommended it back in 2011.
Or 22,097% on Constellation Software.
That helps explain why The Wall Street Journal reported that Weiss Ratings ranked number one, over everyone else covered, including wealth management giants like:
- – Merrill Lynch
- – Deutsche Bank
- – JP Morgan
- – Goldman Sachs
- – Morgan Stanley
Those institutions have millions of customers …
They manage trillions of dollars.
Still, our ratings beat theirs hands down.
Why?
Because Weiss Ratings is the only completely independent, truly unbiased ratings company.
We rate not only stocks, but also ETFs, mutual funds, banks and insurance companies – 53,000 in all. And unlike our big Wall Street competitors, we never accept a dime from the companies or issuers we rate.
Never have and never will.
So when you join Disruptors & Dominators today, you get the combined power of my decades of experiences in Silicon Valley …
And the completely independent Weiss Ratings system – with an average gain of 279% on “Buy”-rated tech stocks in the last two decades.
Take the story I shared with you today.
I used my background as a journalist to uncover an incredible story going on at the FDA.
Certain companies are getting special treatment when it comes to drug approval.
And 97% of the time they were granted First-Class status …
The stock went up.
I was able to identify three promising biotech companies that could completely disrupt the market …
All because of a revolutionary new technology.
When you become a Disruptors & Dominators member today, you’ll get the names of all three of these biotech stocks.
All of the information is in your two special reports:
- The FDA’s Favorite Companies
- The Ultimate AI Drug Stock
You’ll get a new issue of Disruptors & Dominators on the first Friday of every month – each with a brand-new stock market recommendation.
Either someone I believe will dominate the market …
Or a company on the verge of massively disrupting the market.
Like the biotech stocks I’ll share in your special reports.
On top of that, we’ll alert you to any updates or breaking news on the stocks in our portfolio.
And you’ll get free access to our Weiss Ratings for every stock in the market.
Now, there is a cost for Disruptors & Dominators.
But don’t worry.
We’re not going to charge you thousands of dollars.
In fact, we’re not even going to charge you $100.
We want you to get a leg up on the so-called Wall Street “insiders.”
So there’s no reason you shouldn’t get access to the same high quality research and investment analysis.
How do you sign up for Disruptors & Dominators?
But there’s one more unique moneymaking opportunity I’d like to share with you, very quickly …
3 Under the Radar Stocks for the AI Data Center Explosion …
With the advent of AI, data usage has exploded …
Doubling between 2020 and 2023.
In fact, we’re expected to create twice as much data in the next five years …
As we did in the previous decade.
And as AI advances, that number will only go up.
This is becoming a huge problem …
Where are we going to process and store all of that data?
95% of America’s current data centers are NOT equipped to handle AI speeds.
It requires more advanced chips and servers …
Complicated cooling stations and way more space than a typical data center.
Nvidia’s CEO, Jensen Huang, said he expects $1 trillion to be spent on building AI data centers in the next couple of years.
And he believes Amazon, Google, Microsoft and Meta will account for almost all of that spend.
Already, those companies have been buying up space in rural America to build AI data centers.
The focus is shifting from chips to data centers in Big Tech.
Huang mentioned them 56 times in Nvidia’s last earnings call.
2023 saw more AI data centers constructed than ever before.
And it’s still not nearly enough …
The largest tech companies in the world are scrambling to build more every day.
And they’re enlisting the help of a few little-known companies …
These could be the biggest tech stars of the coming months …
Yet very few Americans know their names.
When you subscribe to Disruptors & Dominators today, I’ll send you a third additional bonus report.
3 Under-the-Radar Companies Powering the AI Data Center Explosion.
Inside, I’ll name the three companies who are essential to the massive data center buildout.
- Including an emerging powerhouse that produces components for network infrastructure …
- A designer, from the ground up, of the chips, boards, platforms and even software needed for all AI data center applications.
- And a major data center supplier to technology juggernauts such as Apple and Tesla.
Combined, these under-the-radar companies are just a fraction of the size of Nvidia.
But as their work on AI data centers becomes well-known, we predict their stocks could also become AI superstars.
And they’re all “Buys” right now, according to Weiss Ratings.
We’ll share the full details, including the ticker symbol, in your special report: 3 Under-the-Radar Companies Powering the AI Data Center Explosion.
This report – and your two special biotech reports – are yours as a bonus, when you become a member of Disruptors & Dominators.
Let me quickly summarize all of the benefits you’ll receive today as part of your risk-free membership to Disruptors & Dominators.
- BENEFIT #1. A full 12 months of access to Disruptors & Dominators (sold separately for $109).
- BENEFIT #2. The Next FDA Signal: How to Profit Off First-Class Drugs. (Sold separately for $79)
- BENEFIT #3. The Ultimate AI Drug Stock (Sold separately for $79)
- BENEFIT #4. 3 Under-the-Radar Companies Powering the AI Data Center Explosion. (Sold separately for $79)
- BENEFIT #5. The User’s Guide to Disruptors & Dominators. I’ll explain my unique investing philosophy and how to use it.
- BENEFIT #6. One year of premium access to our 53,000 Weiss Ratings, including not only stocks but also ETFs, mutual fund and other sectors (previously sold separately for $228.)
- BENEFIT #7. My flash alerts for critical, time-sensitive opportunities and warnings (priceless)
- BENEFIT #8. Huge savings! The total value of this package is $574.
But it’s all yours today for just $49.
A savings of over 90% of the retail value. - BENEFIT #9. My Unconditional 100% Money-Back Guarantee.
If you aren’t satisfied at any time for any reason during your first 12 months …
Just call my team and they’ll give you a full refund with no questions asked. You can keep every issue, every bonus report, and every alert you’ve received.
That means you get a full year to try out and enjoy our service. And if you don’t like it, just let us know any time, right up to the very last day of your membership.
One year of Disruptors & Dominators usually retails for $109, and thousands of subscribers pay that price every year.
But with biotech and AI in the headlines every day right now, I don’t want you to miss out.
So, today, you get access to everything for just $49.
That’s less than the cost of a tank of gas. In fact, it’s less than 14 cents per day.
I think you’ll agree that’s more than fair, especially given the quality of research we’re going to share with you today.
Look, the next FDA signal could come any day now.
And if history is any indicator, the stock involved should go up.
Just like it has 74 of the past 76 times.
If you wait around until it’s on the cover of The Wall Street Journal – it will likely be too late.
I’ve uncovered dozens of great tech stocks, long before the market knew about them.
I think I’ve found a few more today …
This biotech breakthrough could be huge for investors in the coming years …
While saving millions of lives in the process.
Now is your chance to get in at practically the ground level.
With Disruptors & Dominators, you’ll have a front row seat for this tech revolution.
Join now …
And get the names of these three breakthrough biotech stocks – and all of your other bonuses, right away.